{"id":"https://openalex.org/W2018500405","doi":"https://doi.org/10.1097/wad.0b013e318266fb02","title":"Patient Adherence to Transdermal Rivastigmine After Switching From Oral Donepezil: A Retrospective Claims Database Study","display_name":"Patient Adherence to Transdermal Rivastigmine After Switching From Oral Donepezil: A Retrospective Claims Database Study","alternate_titles":[],"publication_year":2012,"publication_date":"2012-08-13","ids":{"openalex":"https://openalex.org/W2018500405","doi":"https://doi.org/10.1097/wad.0b013e318266fb02","mag":"2018500405","pmid":"https://pubmed.ncbi.nlm.nih.gov/22892648"},"language":"en","primary_location":{"id":"doi:10.1097/wad.0b013e318266fb02","doi":"https://doi.org/10.1097/wad.0b013e318266fb02","is_oa":false,"landing_page_url":"https://doi.org/10.1097/wad.0b013e318266fb02","pdf_url":null,"source":{"id":"https://openalex.org/S107889856","display_name":"Alzheimer Disease & Associated Disorders","issn_l":"0893-0341","issn":["0893-0341","1546-4156"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Alzheimer Disease &amp; Associated Disorders","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2018500405"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100829713","display_name":"Haijun Tian","orcid":"https://orcid.org/0000-0003-1875-3169","observed_orcids":["https://orcid.org/0000-0003-1875-3169"]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Haijun Tian","raw_affiliation_strings":["Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936-1080, USA","Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936-1080, USA","institution_ids":["https://openalex.org/I4210117619"]},{"raw_affiliation_string":"Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ","institution_ids":["https://openalex.org/I4210117619"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091091674","display_name":"Safiya Abouzaid","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Safiya Abouzaid","raw_affiliation_strings":["Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ","institution_ids":["https://openalex.org/I4210117619"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100344298","display_name":"Wei Chen","orcid":"https://orcid.org/0000-0001-5451-6430","observed_orcids":["https://orcid.org/0000-0001-5451-6430"]},"institutions":[{"id":"https://openalex.org/I4210091341","display_name":"Novartis (China)","ror":"https://ror.org/00fxgea47","country_code":"CN","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210091341"]}],"countries":["CN"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Wei Chen","raw_affiliation_strings":["Greater China Region Medical Affairs, Beijing Novartis Pharmaceuticals Corporation, Beijing, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Greater China Region Medical Affairs, Beijing Novartis Pharmaceuticals Corporation, Beijing, China","institution_ids":["https://openalex.org/I4210091341"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084954969","display_name":"Kristijan H. Kahler","orcid":"https://orcid.org/0000-0002-8227-8879","observed_orcids":["https://orcid.org/0000-0002-8227-8879"]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Kristijan H. Kahler","raw_affiliation_strings":["Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ","institution_ids":["https://openalex.org/I4210117619"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5100728162","display_name":"Edward Kim","orcid":"https://orcid.org/0000-0001-8247-6675","observed_orcids":["https://orcid.org/0000-0001-8247-6675"]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Edward Kim","raw_affiliation_strings":["Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ","institution_ids":["https://openalex.org/I4210117619"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5084954969","https://openalex.org/A5091091674","https://openalex.org/A5100728162","https://openalex.org/A5100829713"],"corresponding_institution_ids":["https://openalex.org/I4210117619"],"apc_list":null,"apc_paid":null,"fwci":1.8197,"has_fulltext":false,"cited_by_count":20,"citation_normalized_percentile":{"value":0.83708392,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"27","issue":"2","first_page":"182","last_page":"186"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11620","display_name":"Medication Adherence and Compliance","score":0.9794999957084656,"subfield":{"id":"https://openalex.org/subfields/2714","display_name":"Family Practice"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11620","display_name":"Medication Adherence and Compliance","score":0.9794999957084656,"subfield":{"id":"https://openalex.org/subfields/2714","display_name":"Family Practice"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10009","display_name":"Dementia and Cognitive Impairment Research","score":0.006399999838322401,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12023","display_name":"Cholinesterase and Neurodegenerative Diseases","score":0.0024999999441206455,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/donepezil","display_name":"donepezil","score":0.9419999718666077},{"id":"https://openalex.org/keywords/treatment-adherence","display_name":"medication adherence","score":0.7369999885559082},{"id":"https://openalex.org/keywords/alzheimer-s-disease","display_name":"Alzheimer's disease","score":0.6589999794960022},{"id":"https://openalex.org/keywords/cholinesterase-inhibitors","display_name":"cholinesterase inhibitors","score":0.7760000228881836},{"id":"https://openalex.org/keywords/drug-switching","display_name":"drug switching","score":0.6510000228881836},{"id":"https://openalex.org/keywords/rivastigmine-patch","display_name":"rivastigmine patch","score":0.9259999990463257},{"id":"https://openalex.org/keywords/proportion-of-days-covered","display_name":"proportion of days covered","score":0.8489999771118164}],"concepts":[{"id":"https://openalex.org/C2776332859","wikidata":"https://www.wikidata.org/wiki/Q411887","display_name":"Rivastigmine","level":5,"score":0.9860881567001343},{"id":"https://openalex.org/C2780904820","wikidata":"https://www.wikidata.org/wiki/Q415081","display_name":"Donepezil","level":4,"score":0.9812179207801819},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6401339769363403},{"id":"https://openalex.org/C2775842315","wikidata":"https://www.wikidata.org/wiki/Q1145270","display_name":"Transdermal patch","level":3,"score":0.6121373772621155},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.4676377773284912},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.45643436908721924},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4242880642414093},{"id":"https://openalex.org/C2779483572","wikidata":"https://www.wikidata.org/wiki/Q83030","display_name":"Dementia","level":3,"score":0.4166313707828522},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.34348064661026},{"id":"https://openalex.org/C205679159","wikidata":"https://www.wikidata.org/wiki/Q3375179","display_name":"Transdermal","level":2,"score":0.23032397031784058},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.1733056902885437}],"mesh":[{"descriptor_ui":"D000068836","descriptor_name":"Rivastigmine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077265","descriptor_name":"Donepezil","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000544","descriptor_name":"Alzheimer Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002800","descriptor_name":"Cholinesterase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007189","descriptor_name":"Indans","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010349","descriptor_name":"Patient Compliance","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":true},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015331","descriptor_name":"Cohort Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D048448","descriptor_name":"Phenylcarbamates","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D057968","descriptor_name":"Transdermal Patch","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/wad.0b013e318266fb02","doi":"https://doi.org/10.1097/wad.0b013e318266fb02","is_oa":false,"landing_page_url":"https://doi.org/10.1097/wad.0b013e318266fb02","pdf_url":null,"source":{"id":"https://openalex.org/S107889856","display_name":"Alzheimer Disease & Associated Disorders","issn_l":"0893-0341","issn":["0893-0341","1546-4156"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Alzheimer Disease &amp; Associated Disorders","raw_type":"journal-article"},{"id":"pmid:22892648","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22892648","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Alzheimer disease and associated disorders","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":22,"referenced_works":["https://openalex.org/W1498917275","https://openalex.org/W1925590521","https://openalex.org/W1971352874","https://openalex.org/W2014091144","https://openalex.org/W2016981346","https://openalex.org/W2026047746","https://openalex.org/W2045413014","https://openalex.org/W2046434435","https://openalex.org/W2046794849","https://openalex.org/W2049884888","https://openalex.org/W2065351367","https://openalex.org/W2074987858","https://openalex.org/W2076676029","https://openalex.org/W2095248985","https://openalex.org/W2100072124","https://openalex.org/W2113976466","https://openalex.org/W2117950925","https://openalex.org/W2122692162","https://openalex.org/W2148461943","https://openalex.org/W2416585725","https://openalex.org/W2429021542","https://openalex.org/W2912402341"],"related_works":["https://openalex.org/W2005789157","https://openalex.org/W2884567560","https://openalex.org/W2320080253","https://openalex.org/W1603277425","https://openalex.org/W2158336542","https://openalex.org/W2082987115","https://openalex.org/W2916585121","https://openalex.org/W1976358724","https://openalex.org/W2001456417","https://openalex.org/W1965905635"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"examine":[2],"patient":[3],"adherence":[4,170,194],"before":[5],"and":[6,24,43,59,64,156],"after":[7,82],"switching":[8,125],"from":[9,70,126,211],"donepezil":[10,41,63,127,203,212],"to":[11,29,47,75,128,159,181,195,213,218],"the":[12,21,48,65,71,76,83,91,100,105,129,140,182,186,214,230],"rivastigmine":[13,49,66,130,141,183,196,215],"patch.":[14],"METHODS:":[15],"This":[16],"retrospective":[17],"cohort":[18],"study":[19],"used":[20],"MarketScan":[22],"Commercial":[23],"Medicare":[25],"data":[26],"sets":[27],"(2004":[28],"2009).":[30],"Patients":[31],"with":[32,95,198,221],"a":[33],"diagnosis":[34],"of":[35,55,73,93,102,166,175,189,233],"Alzheimer":[36],"disease":[37],"who":[38,147,179,200,227],"were":[39,44,51,68,201],"new":[40],"users":[42],"subsequently":[45],"switched":[46,148,180,228],"patch":[50,67,131,142,184,216],"included.":[52],"The":[53,110,121,136],"proportion":[54],"days":[56,94,103],"covered":[57],"(PDC)":[58],"PDC":[60,87,138],"difference":[61],"between":[62,124],"calculated":[69,89],"time":[72,123],"initiation":[74],"switch,":[77],"capped":[78],"at":[79],"1":[80,176],"year":[81,188,232],"first":[84,187,231],"respective":[85,106],"claim.":[86],"was":[88,132,143,171],"as":[90],"number":[92,101],"drugs":[96],"available":[97],"divided":[98],"by":[99],"in":[104,173,225],"follow-up":[107],"periods.":[108],"RESULTS:":[109],"sample":[111],"included":[112],"772":[113],"patients":[114,146,178,226],"(mean":[115],"age":[116],"77":[117],"y;":[118],"58%":[119],"female).":[120],"mean":[122,137],"579":[133],"(SD=317.3)":[134],"days.":[135],"for":[139],"highest":[144],"among":[145],"within":[149,157,185,229],"3":[150],"months":[151,161],"(80.4%":[152],"vs.":[153,163,206],"90.7%;":[154],"P=0.04)":[155],"7":[158],"9":[160],"(61.3%":[162],"71.0%;":[164],"P=0.05)":[165],"initiating":[167,234],"donepezil.":[168,235],"When":[169],"analyzed":[172],"increments":[174],"year,":[177],"treatment":[190],"had":[191],"significantly":[192],"greater":[193],"compared":[197],"those":[199],"on":[202],"(PDC":[204],"69.3%":[205],"60.6%;":[207],"P=0.0004).":[208],"CONCLUSIONS:":[209],"Switching":[210],"seems":[217],"be":[219],"associated":[220],"increased":[222],"adherence,":[223],"especially":[224]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2018500405","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":3}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
